Vertex to Present at the RBC Global Healthcare Conference on February 25
We dive into the process for adding companies and booting them from the iconic index.
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
This screen finds companies ready to take advantage when major provisions of law take effect in 2014.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Week ending Oct. 27: Stocks held in check by jump oil prices, weak housing market.
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.
Increased investor inflows and portfolio reshuffling (driven in part by a fairly valued market), has added breadth to the high-conviction and new-money purchases we've seen so far from our top managers.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...